The HIV Journey
Supporting a Woman’s Lifelong Path Through Pivotal Junctions
Weight and metabolic changes after switching from tenofovir alafenamide (TAF)/emtricitabine (FTC) +dolutegravir (DTG), tenofovir disoproxil fumarate (TDF)/FTC + DTG, and TDF/FTC/efavirenz (EFV) to TDF/lamivudine (3TC)/DTG.
Bosch B, Akpomiemie G, Chandiwana N, et al. Clin Infect Dis. 2023;76(8):1492-1495.
Recommendations for evaluation and management of bone disease in HIV.
Brown TT, Hoy J, Borderi M, et al. Clin Infect Dis. 2015;60(8):1242-1251.
A practical clinical guide to counselling on and managing contraception, pre-conception planning, and menopause for women living with HIV.
Cvetkovic A, King E, Skerritt L, et al. J Assoc Med Microbiol Infect Dis Can. 2021;6(4):278-295.
Bictegravir use during pregnancy: a multicenter retrospective analysis evaluating HIV viral suppression and perinatal outcomes.
Holt LM, Short WR, Momplaisir F, et al. Clin Infect Dis. 2024:ciae218.
A qualitative study of the barriers and enhancers to retention in care for pregnant and postpartum women living with HIV.
Humphrey J, Alera M, Kipchumba B, et al. PLOS Glob Public Health. 2021;1(10):e0000004.
Tirzepatide once weekly for the treatment of obesity.
Jastreboff AM, Aronne LJ, Ahmad NN, et al. N Engl J Med. 2022;387(3):205-216.
Dolutegravir and pregnancy outcomes including neural tube defects in the USA during 2008-20: a national cohort study.
Kourtis AP, Zhu W, Lampe MA, et al. Lancet HIV. 2023;10(9):e588-e596.
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials.
Orkin C, Molina JM, Cahn P, et al. Lancet HIV. 2024;11(2):e75-e85.
A randomized, controlled trial of 3.0 mg of liraglutide in weight management.
Pi-Sunyer X, Astrup A, Fujioka K, et al. N Engl J Med. 2015;373(1):11-22.
Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy.
Rodger AJ, Cambiano V, Bruun T, et al. JAMA. 2016;316(2):171-181.
Final 192-week efficacy and safety results of the ADVANCE Trial, comparing 3 first-line antiretroviral regimens.
Sokhela S, Venter WDF, Bosch B, et al. Open Forum Infect Dis. 2024;11(3):ofae007.
Age at menopause in women living with HIV: a systematic review.
Van Ommen CE, King EM, Murray MCM. Menopause. 2021;28(12):1428-1436.
Once-weekly semaglutide in adults with overweight or obesity.
Wilding JPH, Batterham RL, Calanna S, et al. N Engl J Med. 2021;384(11):989-1002.
Additional HIV-Related CME Activities
Top 10 Key Concepts in Rapid ART: Primary Care and HIV Treater Editions
Building HIV Pathways: Building Bridges to Reach People with HIV Toward the Goal of Re-engagement in Care
Putting Together Clues in HIV, CVD, T2D, and CKD: Escaping Management Mishaps
CLINICAL PRACTICE GUIDELINES
Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society–USA Panel.
Gandhi RT, Bedimo R, Hoy JF, et al. JAMA. 2023;329(1):63-84.
Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV.
US Department of Health and Human Services
CLINICIAN RESOURCES
Immediate ART initiation & restart: guide for clinicians.
AIDS Education and Training Center Program.
Clinical Guidelines Program: HIV treatment
New York State Department of Health AIDS Institute
National Clinician Consultation Center.
University of California, San Francisco.
Published recommendations.
US Preventive Services Task Force.
PATIENT AND CAREGIVER RESOURCES
AIDSMap Resources
NAM Publications
Resources for persons living with HIV
Centers for Disease Control and Prevention
HIV resources
National Institutes of Health
The HIV Journey™
Supporting a Woman’s Lifelong Path Through Pivotal Junctions
| Faculty: | Sarah E. Rowan, MD |
| Release: | 08/21/2024 |
| Expiration: | 08/21/2025 |
